MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
02:30 EST 6 Dec 2012 | Thomson Reuters
This article has expired, however you can still
download the PDF.
Preview:
MorphoSys AG /
MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. MorphoSys AG (FSE: MOR; Prime Standard Segmen...
Other Sources for this Article
More From BioPortfolio on "MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
